#TRexBio
LightNews LightNews
endpts.com
ADARx wants $319M in its IPO as TRexBio and Retension queue up behind it, pushing biotech to its most active year for public debuts since 2021.
ADARx targets $319M IPO as TRexBio, Retension join filing queue
ADARx sets terms for a Nasdaq IPO at $15-$17 a share as Treg biotech TRexBio and hypertension player Retension file for their own floats.
endpoints.news
September 21, 2026 at 7:24 PM
pharmaphorum.bsky.social
The appetite among #USbiotechs for #IPOs shows no signs of being satisfied, with three more companies – #ADARxPharma, #TRexBio, and #RetensionPharma – joining the lunch queue.

pharmaphorum.com/news/adarx-t...
September 22, 2026 at 8:18 AM
longtail-news.bsky.social
Feed: "Endpoints News"
By: Kyle LaHucik on Tuesday, January 27, 2026
TRexBio gets another $50M to bring more Treg candidates into the clinic
Bay Area startup TRexBio has bolstered its 2024 Series B with an additional $50 million to fund the biotech's clinical development in the burgeoning Treg space.
endpoints.news
January 28, 2026 at 12:38 AM
endpts.com
TRexBio has raised another $50M to expand its investment in Treg candidates.
TRexBio gets another $50M to bring more Treg candidates into the clinic
Bay Area startup TRexBio has bolstered its 2024 Series B with an additional $50 million to fund the biotech's clinical development in the burgeoning Treg space.
endpoints.news
January 27, 2026 at 7:23 PM
science.social
TRexBio Secures $84M for Inflammation Therapies - https://biohackers.media/trexbio-secures-84m-for-inflammation-therapies/ - #biohacking #longevity
November 20, 2024 at 4:01 PM